Trials / Not Yet Recruiting

Not Yet RecruitingNCT06221072

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors

Status: Not Yet Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 1,360 (estimated)

Sponsor: Shanghai JMT-Bio Inc. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.

Conditions

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Interventions

Type	Name	Description
DRUG	JMT103	120 mg by subcutaneous injection every 4 weeks
DRUG	zoledronic acid	4 mg by intravenous drip (100mL:4mg) every 4 weeks

Timeline

Start date: 2024-04-05
Primary completion: 2027-05-31
Completion: 2028-05-31
First posted: 2024-01-24
Last updated: 2024-01-24

Source: ClinicalTrials.gov record NCT06221072. Inclusion in this directory is not an endorsement.